Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
SCHJESVOLD, Fredrik H, Meletios-Athanasios DIMOPOULOS, Sosana DELIMPASI, Pawel ROBAK, Daniel CORIU et. al.
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
Authors
SCHJESVOLD, Fredrik H, Meletios-Athanasios DIMOPOULOS, Sosana DELIMPASI, Pawel ROBAK, Daniel CORIU, Wojciech LEGIEC, Luděk POUR, Ivan SPICKA, Tamas MASSZI, Vadim DORONIN, Jiri MINARIK, Galina SALOGUB, Yulia ALEKSEEVA, Antonio LAZZARO, Vladimir MAISNAR, Gabor MIKALA, Laura ROSINOL, Anna Marina LIBERATI, Argiris SYMEONIDIS, Victoria MOODY, Marcus THURESSON, Catriona BYRNE, Johan HARMENBERG, Nicolaas A BAKKER, Roman HAJEK, Maria-Victoria MATEOS, Paul G RICHARDSON and Pieter SONNEVELD
SCHJESVOLD, Fredrik H, Meletios-Athanasios DIMOPOULOS, Sosana DELIMPASI, Pawel ROBAK, Daniel CORIU, Wojciech LEGIEC, Luděk POUR, Ivan SPICKA, Tamas MASSZI, Vadim DORONIN, Jiri MINARIK, Galina SALOGUB, Yulia ALEKSEEVA, Antonio LAZZARO, Vladimir MAISNAR, Gabor MIKALA, Laura ROSINOL, Anna Marina LIBERATI, Argiris SYMEONIDIS, Victoria MOODY, Marcus THURESSON, Catriona BYRNE, Johan HARMENBERG, Nicolaas A BAKKER, Roman HAJEK, Maria-Victoria MATEOS, Paul G RICHARDSON and Pieter SONNEVELD. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. LANCET HAEMATOLOGY. ENGLAND: ELSEVIER SCI LTD, 2022, vol. 9, No 2, p. "E98"-"E110". ISSN 2352-3026. Available from: https://dx.doi.org/10.1016/S2352-3026(21)00381-1.
@article{2247541, author = {Schjesvold, Fredrik H and Dimopoulos, MeletiosandAthanasios and Delimpasi, Sosana and Robak, Pawel and Coriu, Daniel and Legiec, Wojciech and Pour, Luděk and Spicka, Ivan and Masszi, Tamas and Doronin, Vadim and Minarik, Jiri and Salogub, Galina and Alekseeva, Yulia and Lazzaro, Antonio and Maisnar, Vladimir and Mikala, Gabor and Rosinol, Laura and Liberati, Anna Marina and Symeonidis, Argiris and Moody, Victoria and Thuresson, Marcus and Byrne, Catriona and Harmenberg, Johan and Bakker, Nicolaas A and Hajek, Roman and Mateos, MariaandVictoria and Richardson, Paul G and Sonneveld, Pieter}, article_location = {ENGLAND}, article_number = {2}, doi = {http://dx.doi.org/10.1016/S2352-3026(21)00381-1}, keywords = {Published Online; See Comment page e82; Malignancies; University of; Department of Hematology}, issn = {2352-3026}, journal = {LANCET HAEMATOLOGY}, note = {Bez afiliace k MU.}, title = {Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study}, url = {https://www.sciencedirect.com/science/article/pii/S2352302621003811?via%3Dihub}, volume = {9}, year = {2022} }
TY - JOUR ID - 2247541 AU - Schjesvold, Fredrik H - Dimopoulos, Meletios-Athanasios - Delimpasi, Sosana - Robak, Pawel - Coriu, Daniel - Legiec, Wojciech - Pour, Luděk - Spicka, Ivan - Masszi, Tamas - Doronin, Vadim - Minarik, Jiri - Salogub, Galina - Alekseeva, Yulia - Lazzaro, Antonio - Maisnar, Vladimir - Mikala, Gabor - Rosinol, Laura - Liberati, Anna Marina - Symeonidis, Argiris - Moody, Victoria - Thuresson, Marcus - Byrne, Catriona - Harmenberg, Johan - Bakker, Nicolaas A - Hajek, Roman - Mateos, Maria-Victoria - Richardson, Paul G - Sonneveld, Pieter PY - 2022 TI - Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study JF - LANCET HAEMATOLOGY VL - 9 IS - 2 SP - "E98"-"E110" EP - "E98"-"E110" PB - ELSEVIER SCI LTD SN - 23523026 N1 - Bez afiliace k MU. KW - Published Online KW - See Comment page e82 KW - Malignancies KW - University of KW - Department of Hematology UR - https://www.sciencedirect.com/science/article/pii/S2352302621003811?via%3Dihub ER -
SCHJESVOLD, Fredrik H, Meletios-Athanasios DIMOPOULOS, Sosana DELIMPASI, Pawel ROBAK, Daniel CORIU, Wojciech LEGIEC, Luděk POUR, Ivan SPICKA, Tamas MASSZI, Vadim DORONIN, Jiri MINARIK, Galina SALOGUB, Yulia ALEKSEEVA, Antonio LAZZARO, Vladimir MAISNAR, Gabor MIKALA, Laura ROSINOL, Anna Marina LIBERATI, Argiris SYMEONIDIS, Victoria MOODY, Marcus THURESSON, Catriona BYRNE, Johan HARMENBERG, Nicolaas A BAKKER, Roman HAJEK, Maria-Victoria MATEOS, Paul G RICHARDSON and Pieter SONNEVELD. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. \textit{LANCET HAEMATOLOGY}. ENGLAND: ELSEVIER SCI LTD, 2022, vol.~9, No~2, p.~''E98''-''E110''. ISSN~2352-3026. Available from: https://dx.doi.org/10.1016/S2352-3026(21)00381-1.